Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.

source https://medicalxpress.com/news/2023-01-therapy-momelotinib-significant-symptom-anemia.html